PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy

Shares of Plus Therapeutics, Inc. PSTV were up a whopping 311.4% on March 6 after the company announced that the FDA has granted an Orphan Drug Designation (“ODD”) to its lead radiotherapeutic candidate, rhenium (186Re) obisbemeda, for treating leptomeningeal metastases (“LM”) in patients with lung cancer. The stock continued to gain another 51.4% in after-hours trading following the news announcement. The FDA grants ODD to support the...